IRIS
CIVES, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.819
AS - Asia 2.210
EU - Europa 1.788
SA - Sud America 675
Continente sconosciuto - Info sul continente non disponibili 387
AF - Africa 101
OC - Oceania 6
Totale 9.986
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.706
SG - Singapore 854
IT - Italia 658
BR - Brasile 523
CN - Cina 504
HK - Hong Kong 268
SE - Svezia 221
RU - Federazione Russa 197
VN - Vietnam 195
FI - Finlandia 140
FR - Francia 135
DE - Germania 125
GB - Regno Unito 113
IN - India 74
BD - Bangladesh 65
AR - Argentina 57
CA - Canada 52
ID - Indonesia 52
IQ - Iraq 38
NL - Olanda 30
JP - Giappone 29
MX - Messico 29
ZA - Sudafrica 29
TR - Turchia 26
CI - Costa d'Avorio 25
AT - Austria 23
CO - Colombia 22
PL - Polonia 22
UA - Ucraina 22
BE - Belgio 21
PK - Pakistan 19
VE - Venezuela 18
EC - Ecuador 15
ES - Italia 14
IE - Irlanda 13
LT - Lituania 13
PH - Filippine 13
MA - Marocco 12
PY - Paraguay 12
SA - Arabia Saudita 12
CL - Cile 11
BO - Bolivia 7
KE - Kenya 7
UZ - Uzbekistan 7
CR - Costa Rica 6
JO - Giordania 6
MY - Malesia 6
RS - Serbia 6
TN - Tunisia 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
EG - Egitto 5
ET - Etiopia 5
HU - Ungheria 5
MK - Macedonia 5
OM - Oman 5
TH - Thailandia 5
JM - Giamaica 4
PE - Perù 4
AU - Australia 3
BB - Barbados 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KZ - Kazakistan 3
NP - Nepal 3
RO - Romania 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AO - Angola 2
CH - Svizzera 2
DZ - Algeria 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
IL - Israele 2
IS - Islanda 2
LB - Libano 2
MD - Moldavia 2
MM - Myanmar 2
MN - Mongolia 2
MT - Malta 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
IR - Iran 1
JE - Jersey 1
KG - Kirghizistan 1
KR - Corea 1
KY - Cayman, isole 1
LV - Lettonia 1
Totale 9.586
Salva come PNG Salva come JPEG
Città #
Ashburn 592
Fairfield 502
Singapore 460
Woodbridge 389
Hong Kong 263
San Jose 238
Houston 231
Seattle 221
Chandler 210
Cambridge 203
Beijing 202
Milan 191
Nyköping 186
Wilmington 186
Ann Arbor 123
Council Bluffs 123
Helsinki 109
Los Angeles 87
Lauterbourg 78
New York 75
Dallas 69
Rome 69
Lawrence 64
Ho Chi Minh City 63
Jacksonville 61
Roxbury 58
Santa Clara 50
Bari 48
São Paulo 45
Jakarta 41
Nanjing 39
Columbus 37
Des Moines 36
Buffalo 35
Chicago 34
Boardman 33
London 32
Munich 31
Inglewood 28
Hanoi 25
Abidjan 24
Brooklyn 24
Dong Ket 23
Falkenstein 23
Paris 23
Tokyo 23
Redwood City 21
Johannesburg 20
Brussels 19
San Diego 19
Nuremberg 18
Warsaw 18
Brasília 17
Phoenix 17
Montreal 16
Princeton 16
Turin 16
Belo Horizonte 15
Chennai 15
Moscow 15
Orem 15
Curitiba 14
Turku 14
Dublin 13
Frankfurt am Main 13
Buenos Aires 12
Figino 12
Palermo 12
Rio de Janeiro 12
Baghdad 11
Düsseldorf 11
Naples 11
Atlanta 10
Elk Grove Village 10
Mexico City 10
San Francisco 10
Shenyang 10
Stockholm 10
Toronto 10
Vienna 10
Dearborn 9
Haiphong 9
Miami 9
Nanchang 9
Porto Alegre 9
Bologna 8
Can Tho 8
Changsha 8
Denver 8
Medellín 8
Pune 8
Amsterdam 7
Ankara 7
Dhaka 7
Guangzhou 7
Ninh Bình 7
Salt Lake City 7
Shanghai 7
Vibo Valentia 7
Boston 6
Totale 6.334
Salva come PNG Salva come JPEG
Nome #
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors 271
Gastroenteropancreatic Neuroendocrine Tumors 198
Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition 183
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 183
Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity 182
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe 177
Osteotropism of neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro 175
Erdheim-Chester disease: A systematic review. 172
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression 172
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. 170
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications 168
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. 167
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study 165
Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition 162
New insights into the molecular pathogenesis of langerhans cell histiocytosis 161
The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. 159
Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations 157
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 155
An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. 152
NETs: Organ-related epigenetic derangements and potential clinical applications 152
An update on Merkel cell carcinoma 147
Analysis of the immune landscape of small bowel neuroendocrine tumors 144
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors 136
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors 134
Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease 134
Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors 132
The management of refractory carcinoid syndrome: challenges and opportunities ahead 129
SNPs in predicting clinical efficacy and toxicity of chemotherapy: Walking through the quicksand 129
Lenalidomide in multiple myeloma: current experimental and clinical data 125
A phase II study of axitinib in advanced neuroendocrine tumors 125
The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors 123
DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors 122
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials 117
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer 116
Effect of vitaxin on hyperactive osteoclastogenesis in multiple myeloma: a preclinical study 114
Local treatment for focal progression in metastatic neuroendocrine tumors 114
Radionuclide Therapy for Neuroendocrine Tumors 113
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 112
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 112
1101MO Development of CAR T-cells for future treatment of NETs 112
Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice 110
Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems 108
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 108
An update on gastroenteropancreatic neuroendocrine tumors 107
Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. 107
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 107
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 104
Cell fusion in myeloma marrow microenvironment: role in tumor progression 102
Novel Lenalidomide-based combinations for treatment of multiple myeloma 102
In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients 102
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms 102
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 102
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 101
Non-Melanoma Skin Cancers: Biological and Clinical Features 101
Local treatment for focal progression in metastatic neuroendocrine tumors 100
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 99
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours 98
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors 96
Higher frequency of isolated PMS2 loss in colorectal tumors in Colombian population: preliminary results 91
Therapy for locoregional disease: pancreas 91
Management of NETs in the Precision Medicine Era 90
Lanreotide dopo octreotide LAR nel pNET in progressione: descrizione di un caso 90
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%? 88
Sensitivity and Specificity of the NETest: A Validation Study 87
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 84
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 83
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment 83
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML 82
The future of cellular therapy for the treatment of renal cell carcinoma 76
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 75
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 72
An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs 72
EPB41L5 is Associated with the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors 70
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours 68
Neuroendocrine tumors 66
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms 63
A challenge in emergency department: a case report of oxaliplatin-induced Kounis syndrome 57
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 56
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM) 52
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence 50
The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients 50
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France 50
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 48
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial 47
Is NETTER-2 a practice-changing trial? 45
The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion 40
In Defense of Neuroendocrine Tumor Trials 35
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? 34
SPINK2 silencing suppresses leukemic proliferation and restores myeloid commitment via MECOM downregulation in acute myeloid leukaemia 33
White paper on best practices for translational research in neuroendocrine neoplasms 31
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis 31
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries 29
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study 22
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors 18
Totale 9.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022383 0 0 3 10 17 50 14 18 38 37 71 125
2022/2023636 91 111 47 31 37 92 19 87 82 2 17 20
2023/2024313 19 55 14 38 35 63 18 11 6 13 4 37
2024/20251.610 49 27 128 83 57 129 162 129 96 164 207 379
2025/20263.977 557 200 255 472 409 210 380 143 447 379 152 373
2026/2027444 154 176 114 0 0 0 0 0 0 0 0 0
Totale 9.986